Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 1027-1039

  Sikora, Matthew J ^a,b   Strumba, Viktoriya ^c   Lippman, Marc E ^d   Johnson, Michael D ^e   Rae, James M ^a,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Androgen; Aromatase inhibitor; Breast cancer; Endocrine resistance; Estrogen

Indexed keywords

3BETA ANDROSTANEDIOL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; HORMONE ACTION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84868200933     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2032-6     Document Type: Article

References (40)

1. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135-1141. doi:10.1016/S1470-2045 (10) 70257-6
2. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509-518. doi:10.1200/JCO.2009.23.1274
3. Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M (2005) Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 12(Suppl 1):S75-S84. doi:10.1677/erc.1.01023
4. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278(33):30458-30468. doi:10.1074/jbc. M305226200
5. Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80(10):2918-2925
6. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19-34
7. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptorpositive human breast cancer. J Clin Invest 120(7):2406-2413. doi:10.1172/JCI41680
8. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ (2011) Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13(2):R21. doi:10.1186/bcr2833
9. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira S-M, Manning HC, Gonžlez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL (2011) ERadependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-351. doi:10.1158/2159-8290.cd-11- 0101
10. Long BJ, Jelovac D, Thiantanawat A, Brodie AM (2002) The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 8(7):2378-2388
11. Sabnis G, Brodie A (2011) Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol. doi:10.1016/j.mce. 2010.09.005
12. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM (2009) The androgen metabolite 5alpha-androstane-3beta, 17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 115(2):289-296. doi:10.1007/s10549-008-0080-8
13. Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D'Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, De Matteis A (2009) Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 27(19):3192-3197. doi:10.1200/JCO.2008.18.6213
14. Gallicchio L, Macdonald R, Wood B, Rushovich E, Helzlsouer KJ (2011) Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. doi:10.1007/s10549-011-1611-2
15. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS (2003) The pharmacology of letrozole. J Steroid Biochem Mol Biol 87(1):35-45
16. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26(10):1671-1676. doi:10.1200/JCO.2007.13.9279
17. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92(2):141-149. doi:10.1007/s10549-005-1483-4
18. Allegra JC (1965) Lippman ME (1980) The effects of 17b estradiol and tamoxifen on the ZR-75-1 human breast cancer cell line in defined medium. Eur J Cancer 16(8):1007-1015
19. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-delta delta C (T)) method. Methods 25(4):402-408. doi:10.1006/meth.2001.1262
20. Dunbier AK, Martin LA, Dowsett M (2011) New and translational perspectives of oestrogen deprivation in breast cancer. Mol Cell Endocrinol. doi:10.1016/j.mce.2010.12.034
21. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817-9824. doi:10.1074/jbc
22. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC, Ali S (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921-4931. doi:10.1038/sj.onc.1205420
23. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA (2006) Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20(12):3120-3132. doi:10.1210/me.2006-0068
24. Burris HA III (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl 3):10-15
25. Moy B, Goss PE (2006) Lapatinib: current status and future directions in breast cancer. Oncologist 11(10):1047-1057. doi:10.1634/theoncologist.11-10-1047
26. Partridge AH, La Fountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556-562. doi:10.1200/JCO.2007.11. 5451
27. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV (2011) High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to Anti-IGF-IR therapy. Clin Cancer Res 17(8):2314-2327. doi:10.1158/1078-0432.ccr-10-1903
28. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL (2011) A Kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773-6784. doi:10.1158/0008-5472.can-11-1295
29. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM (2010) Deciphering the role of PI3 K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10:S59-S65
30. Sheri A, Martin L-A, Johnston S (2010) Targeting endocrine resistance: Is there a role for mTOR inhibition? Clin Breast Cancer 10:S79-S85
31. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2011) Everolimus in postmenopausal hormone-receptorâ positive advanced breast cancer. N Engl J Med 366(6):520-529. doi:10.1056/NEJMoa1109653
32. Ishikawa T, Takano K, Yasufuku-Takano J, Fujita T, Igarashi T, Miura M, Hata K (2001) Estrogenic impurities in labware. Nat Biotechnol 19(9):812. doi:10.1038/nbt0901-812
33. Du Sell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP (2008) 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22(1):65-77. doi:10.1210/me.2007-0383
34. Dauvois S, Labrie F (1989) Androstenedione and androst-5-ene-3b, 17b-diol stimulate DMBA-induced rat mammary tumors-role of aromatase. Breast Cancer Res Treat 13(1):61-69. doi:10.1007/bf01806551
35. Stanway SJ, Palmieri C, Stanczyk FZ, Folkerd EJ, Dowsett M, Ward R, Coombes RC, Reed MJ, Purohit A (2011) Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. Anticancer Res 31(4):1367-1372
36. Voigt KD, Bartsch W (1986) Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 25 (5 B):749-757
37. Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S (2007) Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72(8):666-671
38. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM (2010) Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 70(8):3278-3286. doi:10.1158/0008-5472.can-09-3024
39. Johnston SR (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(Suppl 1):S28-S36. doi:10.3816/CBC.2009.s.003
40. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594-4600. doi:10.1200/JCO.2010.28.8415